Standard BioTools Inc. (LAB) Current Ratio
- Current ratio · latest quarter: Value 9.10×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.10× | Current assets / current liabilities. $516.87M ÷ $56.80M ≈ 9.10× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 516.87M USD | Assets, Current |
| Current obligations | 56.80M USD | Liabilities, Current |
| Cash and equivalents | 270.03M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 206.69M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 15.75M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 17.10M USD | Inventory, Net |
| Payables | 9.55M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $516.87M | $56.80M | $270.03M | $206.69M | $15.75M | $17.10M | $9.55M | (m) | 9.10× |
| 2026-03-31 | $521.45M | $42.20M | $265.77M | $189.40M | $16.64M | $18.59M | $8.01M | (m) | 12.36× |
| 2025-12-31 | $454.26M | $108.31M | $120.86M | $66.71M | $13.43M | $19.98M | $5.41M | (m) | 4.19× |
| 2025-09-30 | $472.44M | $107.97M | $129.42M | $65.48M | $13.54M | $25.42M | $6.62M | (m) | 4.38× |
| 2025-06-30 | $506.04M | $98.02M | $158.62M | $78.47M | $14.61M | $24.17M | $7.33M | (m) | 5.16× |
| 2025-03-31 | $344.02M | $56.24M | $150.88M | $107.18M | $35.48M | $42.13M | $11.78M | (m) | 6.12× |
| 2024-12-31 | $375.88M | $65.89M | $166.73M | $126.15M | $14.74M | $20.74M | $5.05M | (m) | 5.70× |
| 2024-09-30 | $453.61M | $120.61M | $210.65M | $155.68M | $35.32M | $42.64M | $10.93M | (m) | 3.76× |
| 2024-06-30 | $480.03M | $123.81M | $269.81M | $124.90M | $32.44M | $42.62M | $12.57M | (m) | 3.88× |
| 2024-03-31 | $547.57M | $121.55M | $287.06M | $175.22M | $36.01M | $40.36M | $13.14M | (m) | 4.50× |
| 2023-12-31 | $158.22M | $109.33M | $51.70M | $63.19M | $19.66M | $20.53M | $9.24M | (m) | 1.45× |
| 2023-09-30 | $170.74M | $51.80M | $79.66M | $49.20M | $16.56M | $21.93M | $7.33M | (m) | 3.30× |
| 2023-06-30 | $183.07M | $46.84M | $142.30M | $0.00 | $15.12M | $22.08M | $6.09M | (m) | 3.91× |
| 2023-03-31 | $194.93M | $43.79M | $113.66M | $40.87M | $14.50M | $22.51M | $6.11M | (m) | 4.45× |
| 2022-12-31 | $208.81M | $43.44M | $81.31M | $84.47M | $17.28M | $21.47M | $7.91M | (m) | 4.81× |
| 2022-09-30 | $229.02M | $46.17M | $60.20M | $124.97M | $17.29M | $21.95M | $9.30M | (m) | 4.96× |
| 2022-06-30 | $250.88M | $42.77M | $74.36M | $136.85M | $10.94M | $22.79M | $9.02M | (m) | 5.87× |
| 2022-03-31 | $73.20M | $47.17M | $29.98M | (m) | $15.42M | $23.25M | $12.52M | (m) | 1.55× |
| 2021-12-31 | $72.07M | $49.57M | $28.45M | $0.00 | $18.32M | $20.82M | $10.60M | (m) | 1.45× |
| 2021-09-30 | $73.47M | $47.29M | $29.31M | (m) | $13.73M | $24.50M | $10.79M | (m) | 1.55× |
| 2021-06-30 | $78.21M | $52.85M | $30.86M | (m) | $15.67M | $25.07M | $11.22M | (m) | 1.48× |
| 2021-03-31 | $96.33M | $53.53M | $49.74M | (m) | $15.41M | $21.89M | $12.55M | (m) | 1.80× |
| 2020-12-31 | $117.66M | $54.25M | $68.52M | (m) | $25.42M | $19.69M | $9.22M | (m) | 2.17× |
| 2020-09-30 | $122.66M | $42.79M | $72.34M | (m) | $17.61M | $19.56M | $10.97M | (m) | 2.87× |
| 2020-06-30 | $78.45M | $38.35M | $42.97M | (m) | $9.98M | $18.90M | $9.38M | (m) | 2.05× |
| 2020-03-31 | $82.43M | $35.36M | $34.99M | (m) | $14.41M | $16.29M | $9.44M | (m) | 2.33× |
| 2019-12-31 | $96.10M | $32.82M | $21.66M | (m) | $18.98M | $13.88M | $5.15M | (m) | 2.93× |
| 2019-09-30 | $96.55M | $33.37M | $25.89M | (m) | $14.01M | $15.00M | $5.34M | (m) | 2.89× |
| 2019-06-30 | $106.78M | $37.32M | $24.05M | (m) | $19.26M | $14.27M | $8.07M | (m) | 2.86× |
| 2019-03-31 | $111.48M | $34.18M | $65.63M | (m) | $19.31M | $13.75M | $6.94M | (m) | 3.26× |
| 2018-12-31 | $127.11M | $37.58M | $95.40M | (m) | $16.65M | $13.00M | $4.03M | (m) | 3.38× |
| 2018-09-30 | $71.86M | $38.87M | $35.83M | (m) | $18.38M | $15.42M | $6.25M | (m) | 1.85× |
| 2018-06-30 | $75.25M | $36.65M | $39.42M | (m) | $16.87M | $15.25M | $6.64M | (m) | 2.05× |
| 2018-03-31 | $81.00M | $33.70M | $41.97M | (m) | $16.27M | $15.25M | $5.21M | (m) | 2.40× |
| 2017-12-31 | $94.80M | $33.47M | $58.06M | (m) | $15.05M | $15.09M | $4.21M | (m) | 2.83× |
| 2017-09-30 | $96.17M | $31.88M | $60.94M | (m) | $13.73M | $17.75M | $4.72M | (m) | 3.02× |
| 2017-06-30 | $79.13M | $34.32M | $39.60M | (m) | $13.66M | $18.77M | $3.86M | (m) | 2.31× |
| 2017-03-31 | $86.11M | $31.29M | $44.10M | (m) | $14.39M | $19.71M | $3.73M | (m) | 2.75× |
| 2016-12-31 | $96.67M | $29.50M | $35.05M | (m) | $14.61M | $20.11M | $3.97M | (m) | 3.28× |
| 2016-09-30 | $108.09M | $27.91M | $32.31M | (m) | $12.84M | $20.84M | $4.87M | (m) | 3.87× |
| 2016-06-30 | $127.04M | $32.31M | $35.90M | (m) | $18.89M | $18.18M | $5.83M | (m) | 3.93× |
| 2016-03-31 | $137.80M | $30.52M | $42.85M | (m) | $19.64M | $19.57M | $4.44M | (m) | 4.52× |
| 2015-12-31 | $144.09M | $30.08M | $29.12M | (m) | $25.46M | $17.92M | $6.09M | (m) | 4.79× |
| 2015-09-30 | $145.45M | $27.48M | $28.82M | (m) | $26.25M | $19.14M | $6.30M | (m) | 5.29× |
| 2015-06-30 | $143.38M | $28.93M | $23.75M | (m) | $21.79M | $18.82M | $5.96M | (m) | 4.96× |
| 2015-03-31 | $155.23M | $24.90M | $36.98M | (m) | $19.58M | $17.39M | $5.50M | (m) | 6.23× |
| 2014-12-31 | $155.90M | $29.39M | $33.71M | (m) | $22.38M | $15.99M | $5.92M | (m) | 5.31× |
| 2014-09-30 | $132.82M | $27.31M | $30.94M | (m) | $16.92M | $16.96M | $7.28M | (m) | 4.86× |
| 2014-06-30 | $127.43M | $27.31M | $43.68M | (m) | $13.33M | $16.36M | $7.64M | (m) | 4.67× |
| 2014-03-31 | $178.81M | $25.74M | $101.02M | (m) | $18.79M | $13.43M | $8.00M | (m) | 6.95× |
| 2013-12-31 | $104.58M | $17.95M | $35.26M | (m) | $10.55M | $8.15M | $4.35M | (m) | 5.83× |
| 2013-09-30 | $86.66M | $15.04M | $20.10M | (m) | $12.41M | $8.02M | $3.41M | (m) | 5.76× |
| 2013-06-30 | $80.54M | $11.63M | $32.29M | (m) | $10.84M | $7.23M | $2.00M | (m) | 6.93× |
| 2013-03-31 | $98.56M | $11.54M | $61.81M | (m) | $10.06M | $7.37M | $3.21M | (m) | 8.54× |
| 2012-12-31 | $101.21M | $11.60M | $58.65M | (m) | $12.90M | $7.17M | $2.56M | (m) | 8.73× |
| 2012-09-30 | $105.54M | $13.13M | $66.01M | (m) | $10.65M | $7.22M | $3.35M | $0.00 | 8.04× |
| 2012-06-30 | $55.70M | $14.77M | $9.85M | (m) | $9.61M | $6.61M | $3.29M | $2.83M | 3.77× |
| 2012-03-31 | $56.66M | $17.74M | $8.50M | (m) | $9.76M | $6.44M | $4.10M | $6.34M | 3.19× |
| 2011-12-31 | $70.03M | $20.17M | $13.55M | (m) | $9.25M | $5.97M | $4.01M | $8.92M | 3.47× |
| 2011-09-30 | $76.03M | $19.66M | $11.88M | $47.05M | $8.97M | $5.84M | $4.68M | $8.60M | 3.87× |
| 2011-06-30 | $80.99M | $17.76M | $10.13M | $54.22M | $10.32M | $4.85M | $2.98M | $8.31M | 4.56× |
| 2010-12-31 | $20.88M | $18.51M | $5.72M | (m) | $8.10M | $4.89M | $3.15M | $4.56M | 1.13× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |